(Reuters) -     Regeneron Pharmaceuticals Inc reportedÂ an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales. (Reporting by Aditya Samal and Raghav Mahobe in Bengaluru; Editing by Maju Samuel)